Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

RCT of Neurocognitive and Neuroimaging Biomarkers: Predicting Progression Towards Dementia in Patients With Treatment-resistant Late-life Depression (OPTIMUM-Neuro RCT)

NCT05531591 is registered in ClinicalTrials.gov with Centre for Addiction and Mental Health as lead sponsor.

NCT NCT05531591
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05531591 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
RCT of Neurocognitive and Neuroimaging Biomarkers: Predicting Progression Towards Dementia in Patients With Treatment-resistant Late-life Depression (OPTIMUM-Neuro RCT)
Lead sponsor
Centre for Addiction and Mental Health
Phase
Phase 4
Overall status
Completed
Start date
August 1, 2019
Completion date
July 31, 2024
Enrollment
87 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

dementia, depression, geriatric depression, late life depression, major depressive disorder, mild cognitive impairment, treatment resistant depression, treatment-refractory depression